To read the full story, subscribe or sign in.

Message delivery: Replicate Bioscience closes $40M series A for self-replicating RNA

Sep. 8, 2021

Replicate Bioscience Inc. secured a $40 million series A round to take a portfolio of preclinical projects employing self-replicating RNA into the clinic.

BioWorld Financings Cancer Inflammatory Series A

Today's news in brief

BioWorld

BioWorld briefs for July 2, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 2, 2025.

AI-generated illustration of CAR T cells

Researchers arm CAR T cells to fight solid tumors

BioWorld

Aussie researchers have used CRISPR gene editing tools to “armor” chimeric antigen receptor (CAR) T cells to activate additional cancer-fighting proteins at the...

Bioversys, Shionogi in CHF529M lung infection collaboration

BioWorld Science

Antibiotics specialist Bioversys AG has sealed a potential CHF529 million (US$667.5 million) deal with Shionogi Co. Ltd., in which they will work together on...

Medtronic receives CE mark for its Vitalflow ECMO system

BioWorld MedTech

Medtronic plc received a CE mark for its Vitalflow extracorporeal membrane oxygenation (ECMO) system, which provides temporary support for the heart and lungs in...